CN Patent

CN120514706A — 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法

Assigned to Karuna Therapeutics Inc · Expires 2025-08-22 · 1y expired

What this patent protects

本文提供了一种在有需要的患者中治疗精神分裂症或与精神分裂症相关的疾病的方法。该方法包括经由滴定方案每天两次向该患者口服施用口服药物组合物，该口服药物组合物包含多个含呫诺美林或其盐的呫诺美林珠、以及多个含曲司氯胺盐的曲司氯胺珠，该滴定方案包括增加滴定该呫诺美林或其盐、以及该曲司氯胺盐。

USPTO Abstract

本文提供了一种在有需要的患者中治疗精神分裂症或与精神分裂症相关的疾病的方法。该方法包括经由滴定方案每天两次向该患者口服施用口服药物组合物，该口服药物组合物包含多个含呫诺美林或其盐的呫诺美林珠、以及多个含曲司氯胺盐的曲司氯胺珠，该滴定方案包括增加滴定该呫诺美林或其盐、以及该曲司氯胺盐。

Drugs covered by this patent

Patent Metadata

Patent number: CN120514706A
Jurisdiction: CN
Classification: —
Expires: 2025-08-22
Drug substance claim: No
Drug product claim: No
Assignee: Karuna Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.